• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Prenatal fish oil supplementation associated with lower risk of asthma in children: The COPSAC trial

byMatthew Lin, MDandShaidah Deghan, MSc. MD
December 29, 2016
in Obstetrics, Pediatrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Third trimester supplementation with long-chain polyunsaturated fatty acids (LCPUFA) reduces offspring risk of asthma or persistent wheeze and risk of lower respiratory tract infections (LRTI).

Evidence Rating Level: 1 (excellent)  

Study Rundown: Asthma is a chronic disease that affects approximately 20% of young children, with the cost of care for these patients between 2005 and 2009 estimated as a little over $10 billion. The association between poor prenatal intake of n-3 LCPUFAs and increased risk of asthma in offspring has been suggested by observational studies, but randomized controlled trials have offered mixed results. In the Copenhagen Prospective Studies on Asthma in Childhood (COPSAC), researchers aimed to determine if supplementation of n-3 LCPUFAs in pregnant women during their trimester would reduce the risk of asthma in their offspring up to 5 years of age. The results demonstrated that third trimester n-3 LCPUFA supplementation reduced the absolute risk of asthma and LRTI (i.e. bronchitis, pneumonia) in offspring. Specifically, the risk of asthma in offspring was reduced by 6%, and this effect was most pronounced in women with low pre-study levels of omega-3 fatty acids. The number needed to treat to prevent one case of asthma was 14.6 in the total cohort. Overall, the trial is well-powered with good longitudinal follow-up but with some recruitment bias (participants vs. nonparticipants differed in employment and income level). The clinical implications of this study suggests that prenatal supplementation with n-3 LCPUFAs may contribute to the prevention of asthma and respiratory infections in young children.

Click to read the study, published today in NEJM

Relevant Reading: The global burden of asthma: executive summary of the GINA Dissemination Committee Report

In-Depth [randomized controlled trial]: In this single-center, double-blind placebo-controlled trial, 736 women between 22-26 weeks of gestation were randomly assigned to receive either n-3 LCPUFA (fish oil) or placebo (olive oil) daily up until 1 week after delivery. The final study included 695 children and pediatricians collected clinical data for visits at 1 week after birth, then at 1, 3, 6 months and every 6 months until 36 months and then yearly after until 5 years. A total of 95.5% of children completed the 3-year double-blind follow-up. The primary endpoint was risk of asthma, which was 16.9% vs. 23.7% in the n-3 LCPUFA and placebo groups, respectively (HR 0.69; 95%CI 0.49-0.97; p = 0.035). In a subgroup analysis that stratified women by pre-intervention levels of omega-3 fatty acids, the study showed that this protective effect against asthma was strongest in women with the lowest pre-intervention levels of omega-3 fatty acids. Secondary endpoints included risk of LRTI, asthma exacerbations, eczema or allergic sensitization. Supplementation reduced risk of LRTIs in the treatment compared to the control group (31.7% vs 39.1%; HR 0.75; 95%CI 0.58-0.98; p = 0.033), however, there was no significant association between groups for asthma exacerbations, eczema or allergic sensitization.

Image: CC/Wiki

RELATED REPORTS

Treating mild chronic hypertension associated with better pregnancy outcome

Prenatal medication for opioid use disorder helps discharge infants back to mothers

Wellness Check: Addictions

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: fish oilpregnancy
Previous Post

Intensive outpatient care teams did not reduce acute care use

Next Post

Cardiovascular outcomes are similar for arthritis patients treated with selective and nonselective NSAIDs

RelatedReports

Prenatal antidepressant exposure may increase risk of poor motor development
Cardiology

Treating mild chronic hypertension associated with better pregnancy outcome

May 13, 2022
Prenatal antidepressant exposure may increase risk of poor motor development
Chronic Disease

Prenatal medication for opioid use disorder helps discharge infants back to mothers

April 22, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Wellness

Wellness Check: Addictions

April 21, 2022
Women electing abortion more likely to be victims of domestic violence
Chronic Disease

Presence of second midwife during the second active stage of labour reduces the risk of severe perineal trauma

April 7, 2022
Next Post
Placebo formulation impacts effectiveness of pain control in osteoarthritis

Cardiovascular outcomes are similar for arthritis patients treated with selective and nonselective NSAIDs

PCI not superior to medical therapy alone in stable coronary disease: The COURAGE study

No significant difference found at 5-year follow-up between bilateral and single CABG: The ART trial

Earlier puberty associated with increased risk of depression in girls

Effect of a primary care-based psychological intervention on common mental disorders in Zimbabwe

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]
  • Relugolix combination therapy is efficacious for endometriosis-associated pain
  • Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.